A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

Exclusion Criteria

• •History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
• •Participants in a severely immunocompromised state
• •Participants with severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease
• •Participants having active severe infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections
• •Participants who had a live vaccine fewer than 4 weeks before first dose of rituximab
• •Any other condition which puts the participant to undue risk for rituximab therapy as per local prescribing information or Investigator's judgment
• •Participants with any previous treatment with rituximab
• •Participants with any previous treatment with alemtuzumab
• •Participants who have had treatment with infliximab within the previous 3 months
• •Participants who have had treatment with adalimumab within the previous 2 months
• •Participants who have had treatment with etanercept within the previous month
• •Participants with any other investigational medication within the previous month